The FLOW studies have shown that SMG significantly reduces cardiovascular and renal adverse events, regardless of history of heart failure, initial severity of kidney disease, or concomitant use of Sodium Glucose Cotransporter 2 (SGLT2) inhibitors [139,140,141,142]. The gene discussed is SLC5A2; the disease is heart failure.